Trial Profile
A Randomized Trial to Investigate the Efficacy and Safety of Mirabegron Dose Escalation from 25 to 50 mg in Asian Overactive Bladder (OAB) Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 May 2018
Price :
$35
*
At a glance
- Drugs Mirabegron (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- 21 May 2018 Results presented at the 113th Annual Meeting of the American Urological Association.
- 21 May 2018 New trial record